Physician profile
Keisha A Yahagi
NPI 1073953394
$7,512.07
in general payments reported to CMS, 2019-2025
16 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $178 · 2021: $918 · 2022: $1,307 · 2023: $1,148 · 2024: $1,756 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,574.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.68 | 2021-2025 | Vraylar |
| Alkermes, INC. | $888.07 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $836.54 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $748.84 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $664.94 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $642.38 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $638.17 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $552.22 | 2020-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $537.27 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $443.76 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $336.66 | 2021-2022 | |
| Lundbeck LLC | $148.42 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $30.69 | 2019-2020 | |
| Eisai INC. | $22.72 | 2021 | |
| Luye Pharma (USA) LTD. | $18.58 | 2025 | Erzofri Extended-Release |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.13 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keisha Yahagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.